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COST-UTILITY ANALYSIS OF THE TREATMENT
OF RELAPSING-REMITTING MULTIPLE
SCLEROSIS WITH GLATIRAMER ACETATE OR
INTERFERON BETA IN SPAIN
Rubio-Terrés C1, Medina F2,Aristegui I1, Izquierdo G2
1Aventis Pharma, S.A, Madrid, Spain; 2Hospital Universitario
Virgen Macarena, Sevilla, Spain
OBJECTIVE: To carry out a cost-utility analysis of 
the treatment of relapsing-remitting multiple sclerosis
(RRMS) with glatiramer acetate (Copaxone) or interferon
beta products (all as a whole, Avonex, Rebif and
Betaferon). METHODS: Markov pharmacoeconomic
model that compared treatments by simulating the life 
of a hypothetical cohort of 30-year-old women, from 
the societal perspective. Transition probabilities, utilities,
resource utilization and costs (direct and indirect) were
estimated from Spanish sources and bibliography. Simple
univariate sensitivity analyses of the base case were per-
formed. RESULTS: In the base case analysis, the average
cost per patient (€ in 2001) of life treatment, considering
a life expectancy of 53 years, would be €1,243,906
€1,818,149, €1,763,263, €1,987,153 and €1,704,031
with Copaxone, all the interferons, Avonex, Rebif and
Betaferon, respectively. Thus, the savings with Copaxone
would range from €460,000 to €737,000 approximately.
The quality-adjusted life years (QALY) obtained with
Copaxone or the interferons would be 10.977 and 6.917,
respectively, with a mean gain of 4.060 QALY/patient
with Copaxone. Sensitivity analyses conﬁrmed the
robustness of the base case. Interferons would be supe-
rior to Copaxone only in the hypothetical and unlikely
case that they delay the progression of the illness by 20%
more than that presently observed in the clinical trials.
CONCLUSIONS: For a typical patient with RRMS,
treatment with Copaxone would be more efﬁcient than
interferons, which would be dominated by the former
(Copaxone would be more effective with lower costs than
the latter).
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THE COMPARISON OF DIFFERENT METHODS
FOR DETERMINING THE IMPACT OF MIGRAINE
PROPHYLAXIS ON COSTS
Barlev A1, Globe D1,Wu EQ2,Yu W3, Johnson KA1
1University of Southern California, Los Angeles, CA, USA;
2Analysis Group/Economics, Boston, MA, USA; 3WellPoint
Pharmacy Management, West Hills, CA, USA
OBJECTIVES: Compare different approaches to assess-
ing the association of prophylactic treatment and total
migraine-speciﬁc costs from administrative data. Evalu-
ate the usefulness of propensity scores. METHODS:
Using retrospective, administrative data, two groups of
patients were identiﬁed: 1) received prophylactic migraine
treatment; and 2) potential candidates for prophylaxis.
Four methods were applied to compare the log of the total
migraine cost between the groups, and to determine the
association of prophylaxis with total cost. In the ﬁrst
method, groups were matched based on logit propensity
score to adjust for selection bias. In the second, groups
were exact case matched on the same variables. In the
third method a linear regression model was constructed
using all observations in the data. A comparison between
the means of total migraine cost, and log of total migraine
cost was also evaluated based on a T-test without adjust-
ment for selection bias. Jackknife residual analysis was
performed, and statistically signiﬁcant outliers were elim-
inated. RESULTS: As typical for cost data, the total
migraine cost data was skewed, so the data was log trans-
formed. Results based on different methods showed the
same trend; patients treated with migraine prophylaxis
had lower total migraine cost. Mean differences (p-value)
in total migraine cost and log cost, between the groups,
without adjustment for selection bias, were $263
(0.0306) and 0.3192 (<0.0001). Log total migraine cost
showed a 29% (<0.0001) (linear regression), 33.5%
(<0.0001) (propensity scores method), and 29.6%
(<0.0001) (case matched method) reduction in cost for
those on prophylaxis. CONCLUSION: The construction
of a propensity score model is more complicated and may
result in some data loss. The ability of the model to adjust
for selection bias depends on how well the propensity
score model predicts the treatment variable. The con-
straints in this retrospective, administrative data limit the
usefulness of this approach.
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THE ECONOMIC BURDEN OF MIGRAINE AND
COMORBID MENTAL CONDITIONS: RESULTS
FROM A CASE-CONTROL STUDY
Pesa JA1, Lage MJ2
1AstraZeneca LP, Wilmington, DE, USA; 2HealthMetrics
Outcomes Research, L.L.C, Groton, CT, USA
OBJECTIVES: To examine the direct and indirect costs
for adults diagnosed with migraine, as well as the costs
associated with comorbid anxiety and/or depression.
METHODS: Individuals diagnosed with migraine or
receiving a migraine medication between 1999–2000
were identiﬁed in a database capturing inpatient, outpa-
tient, and prescription drug services from approximately
45 large employers. The migraine cohort (N = 2519) was
matched to a non-migraine cohort (N = 2519) at a 1 :1
ratio based upon age, gender and metropolitan statistical
area. Variables of interest included direct medical costs
(inpatient, outpatient, and prescription drug) as well as
indirect costs (absenteeism, short-term disability and
worker compensation). RESULTS: Adults with migraine
had signiﬁcantly higher inpatient (p = 0.0008), outpatient
(p < 0.0001), prescription drug (p < 0.0001), and overall
medical costs (p < 0.0001) compared to the non-migraine
cohort. In addition, adults with migraine had signiﬁcantly
higher costs associated with absenteeism (p = 0.0010)
compared to the healthy cohort. The presence of depres-
